Overexpression of 14-3-3ζ in cancer cells activates PI3K via binding the p85 regulatory subunit

Oncogene

Volumn 31, Issue 7, 2012, Pages 897-906

  Neal, C L ^a   Xu, J ^a,b   Li, P ^a   Mori, S ^a   Yang, J ^a,b   Neal, N N ^a   Zhou, X ^a   Wyszomierski, S L ^a   Yu, D ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

14 3 3 ; Akt; breast cancer; PI3K

Indexed keywords

ALANINE; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN 14 3 3; PROTEIN 14 3 3 ZETA; PROTEIN KINASE B; PROTEIN P85; SERINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CELL ANCHORAGE; CELL MEMBRANE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME BINDING; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; TUMOR PROMOTION; TUMOR XENOGRAFT;

14-3-3 PROTEINS; AMINO ACID SUBSTITUTION; ANIMALS; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; MUTATION; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE;

EID: 84857113294     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.284     Document Type: Article

References (32)

1. Aitken A. (1995). 14-3-3 proteins on the MAP. Trends Biochem Sci 20: 90-97.
2. Aitken A. (2006). 14-3-3 proteins: a historic overview. Semin Cancer Biol 16: 162-172. (Pubitemid 43796128)
3. Barboric M, Kohoutek J, Price JP, Blazek D, Price DH, Peterlin BM. (2005). Interplay between 7SK snRNA and oppositely charged regions in HEXIM1 direct the inhibition of P-TEFb. Embo J 24: 4291-4303. (Pubitemid 41828904)
4. Benzinger A, Muster N, Koch HB, Yates III JR, Hermeking H. (2005). Targeted proteomic analysis of 14-3-3 sigma, a p53 effector commonly silenced in cancer. Mol Cell Proteomics 4: 785-795. (Pubitemid 40873007)
5. Bonnefoy-Berard N, Liu YC, von Willebrand M, Sung A, Elly C, Mustelin T et al. (1995). Inhibition of phosphatidylinositol 3-kinase activity by association with 14-3-3 proteins in T cells. Proc Natl Acad Sci USA 92: 10142-10146.
6. Brachmann SM, Yballe CM, Innocenti M, Deane JA, Fruman DA, Thomas SM et al. (2005). Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement. Mol Cell Biol 25: 2593-2606. (Pubitemid 40381624)
7. Cantley LC. (2002). The phosphoinositide 3-kinase pathway. Science 296: 1655-1657. (Pubitemid 34579158)
8. Cosentino C, Di Domenico M, Porcellini A, Cuozzo C, De Gregorio G, Santillo MR et al. (2007). p85 regulatory subunit of PI3K mediates cAMP-PKA and estrogens biological effects on growth and survival. Oncogene 26: 2095-2103. (Pubitemid 46514751)
9. Craparo A, Freund R, Gustafson TA. (1997). 14-3-3 (epsilon) interacts with the insulin-like growth factor I receptor and insulin receptor substrate I in a phosphoserine-dependent manner. J Biol Chem 272: 11663-11669. (Pubitemid 27184180)
10. Danes CG, Wyszomierski SL, Lu J, Neal CL, Yang W, Yu D. (2008). 14-3-3 zeta down-regulates p53 in mammary epithelial cells and confers luminal filling. Cancer Res 68: 1760-1767. (Pubitemid 351416561)
11. De Gregorio G, Coppa A, Cosentino C, Ucci S, Messina S, Nicolussi A et al. (2007). The p85 regulatory subunit of PI3K mediates TSHcAMP-PKA growth and survival signals. Oncogene 26: 2039-2047. (Pubitemid 46514747)
12. Jin J, Smith FD, Stark C, Wells CD, Fawcett JP, Kulkarni S et al. (2004). Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Curr Biol 14: 1436-1450. (Pubitemid 39123741)
13. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. (2001). Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17: 615-675. (Pubitemid 33096187)
14. Kim SJ, Cheon SH, Yoo SJ, Kwon J, Park JH, Kim CG et al. (2005). Contribution of the PI3K/Akt/PKB signal pathway to maintenance of self-renewal in human embryonic stem cells. FEBS Lett 579: 534-540. (Pubitemid 40092440)
15. Lonic A, Barry EF, Quach C, Kobe B, Saunders N, Guthridge MA. (2008). Fibroblast growth factor receptor 2 phosphorylation on serine 779 couples to 14-3-3 and regulates cell survival and proliferation. Mol Cell Biol 28: 3372-3385. (Pubitemid 351657100)
16. Lu J, Guo H, Treekitkarnmongkol W, Li P, Zhang J, Shi B et al. (2009). 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell 16: 195-207.
17. Munday AD, Berndt MC, Mitchell CA. (2000). Phosphoinositide 3-kinase forms a complex with platelet membrane glycoprotein Ib-IX-V complex and 14-3-3zeta. Blood 96: 577-584. (Pubitemid 30463378)
18. Muslin AJ, Tanner JW, Allen PM, Shaw AS. (1996). Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 84: 889-897. (Pubitemid 26106858)
19. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA et al. (2004). PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127. (Pubitemid 39485684)
20. Neal CL, Yao J, Yang W, Zhou X, Nguyen NT, Lu J et al. (2009). 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res 69: 3425-3432.
21. Oksvold MP, Huitfeldt HS, Langdon WY. (2004). Identification of 14-3-3zeta as an EGF receptor interacting protein. FEBS Lett 569: 207-210. (Pubitemid 38844619)
22. Porter GW, Khuri FR, Fu H. (2006). Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Semin Cancer Biol 16: 193-202. (Pubitemid 43796125)
23. Pozuelo Rubio M, Geraghty KM, Wong BH, Wood NT, Campbell DG, Morrice N et al. (2004). 14-3-3-affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking. Biochem J 379: 395-408. (Pubitemid 38570113)
24. Tan M, Yao J, Yu D. (1997). Overexpression of the c-erbB-2 gene enhanced intrinsic metastatic potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 57: 1199-1205. (Pubitemid 27138623)
25. Tzivion G, Avruch J. (2002). 14-3-3 proteins: active cofactors in cellular regulation by serine/threonine phosphorylation. J Biol Chem 277: 3061-3064. (Pubitemid 34953163)
26. Tzivion G, Gupta VS, Kaplun L, Balan V. (2006). 14-3-3 proteins as potential oncogenes. Semin Cancer Biol 16: 203-213. (Pubitemid 43810260)
27. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. (2005). Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 30: 194-204. (Pubitemid 40463309)
28. van Hemert MJ, Steensma HY, van Heusden GP. (2001). 14-3-3 proteins: key regulators of cell division, signalling and apoptosis. Bioessays 23: 936-946. (Pubitemid 32972693)
29. Wilker E, Yaffe MB. (2004). 14-3-3 Proteins-a focus on cancer and human disease. J Mol Cell Cardiol 37: 633-642. (Pubitemid 39194555)
30. Yaffe MB. (2002). How do 14-3-3 proteins work?-Gatekeeper phosphorylation and the molecular anvil hypothesis. FEBS Lett 513: 53-57. (Pubitemid 34242978)
31. Yaffe MB, Rittinger K, Volinia S, Caron PR, Aithen A, Jeffers H et al. (1997). The structural basis for 14-3-3: phosphopeptide binding specificity. Cell 91: 961-971. (Pubitemid 28027829)
32. Yu J, Zhang Y, McIlroy J, Rordorf-Nikolic T, Orr GA, Backer JM. (1998). Regulation of the p85/p110 phosphatidylinositol 30-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 18: 1379-1387. (Pubitemid 28100902)